Analyses / PATH
Mid-cap software name, down 5.7% on the session and near its day low. Growth is intact, but insider selling and thin margin data keep the read mixed.
A free account reveals PATH's entry zone, price target & stop loss. Full 1-week to 1-year price forecasts are included with Pro.
The Thesis
▲ Bull Case
In a bull scenario, revenue growth of 15% (5-year 21.5%) and an 83% gross margin keep the software growth thesis intact. Trailing P/E of 17.8 and price-to-free-cash-flow of 18.3 are not stretched for that growth. The stock sits about 30% up its 52-week range, leaving room to recover toward the prior close of 13.14 and the day high of 13.09. Operating margin expansion from 3.5% would strengthen the case.
▼ Bear Case
In a bear scenario, the stock fell 5.7% and closed at its day low. Insiders recorded 78 sell transactions (42.8M shares) against 17 buys (33.7M shares). Forward P/E of 22.9 sits above trailing 17.8, which may signal lower expected earnings. Operating margin of 3.5% leaves little cushion, and EV/EBITDA of 101x looks stretched. A break below the 52-week low of 9.20 would be a notable technical failure.
Valuation
FAIRLY PRICED — score 50/100
Trailing multiples look moderate, but forward P/E is higher and EV/EBITDA is unreliable given the margin data gap.
Technical Levels
Support · $12.39 (Current price and day low) · $12.96 (Session open) · $9.20 (52-week low)
Resistance · $13.09 (Day high) · $13.14 (Prior close) · $19.84 (52-week high)
RSI: Unavailable in provider payload
Financial Health
Score 60/100. Liquidity ratios are solid. Leverage and coverage data are missing, so the balance sheet read is incomplete.
Catalysts
| Gemini Healthcare tie-up question raised in recent coverage | Recent news; timing not specified | unclear |
| AI cost positioning versus software peers | Recent coverage | medium |
| Next earnings report date | Not in provider payload | high |
Risk Flags
See PATH's full trade plan — free
Create a free account to unlock the exact entry, target, and stop — plus run live analysis on any of 5,000+ tickers. No card required.
Unlock PATH free →Recent News
- UiPath (PATH) Declines More Than Market: Some Information for InvestorsYahoo
- UiPath Stock And Other Software Picks Built For Higher AI CostsYahoo
- Is Trending Stock UiPath, Inc. (PATH) a Buy Now?Yahoo
- Fastly vs. UiPath: Which Artificial Intelligence Stock Is a Better Buy Going into 2027?Yahoo
- A $548 Million Reason to Watch Qualcomm Stock HereYahoo
You've read your 2 free analyses
Create a free account for unlimited analyses — every name on the page, plus live tools on 5,000+ tickers. No card required.
Read the full PATH analysis — free →Free to read · 2 analyses every 30 days without an account
More Analyses
PATH FAQ
Is PATH a buy right now?
UiPath Inc's current read is a Mixed recovery watch setup with low confidence over a 3m horizon. Valuation: FAIRLY PRICED. See the full bull and bear case above, or run a live analysis for the exact entry, target and stop.
Is PATH overvalued?
FAIRLY PRICED (valuation score 50/100). Trailing multiples look moderate, but forward P/E is higher and EV/EBITDA is unreliable given the margin data gap.
What are the risks of buying PATH?
In a bear scenario, the stock fell 5.7% and closed at its day low. Insiders recorded 78 sell transactions (42.8M shares) against 17 buys (33.7M shares). Forward P/E of 22.9 sits above trailing 17.8, which may signal lower expected earnings. Operating margin of 3.5% leaves little cushion, and EV/EBITDA of 101x looks stretched. A break below the 52-week low of 9.20 would be a notable technical failure.